Herman, S. E. M., Montraveta, A., Niemann, C. U., Mora-Jensen, H., Gulrajani, M., Krantz, F., . . . Woyach, J. A. (2016). The Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia. Clin Cancer Res.
Styl cytowania ChicagoHerman, Sarah E. M., et al. "The Bruton’s Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia." Clin Cancer Res 2016.
Styl cytowania MLAHerman, Sarah E. M., et al. "The Bruton’s Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia." Clin Cancer Res 2016.